succinobucol

(redirected from AGI-1067)

succinobucol

An antioxidant and anti-inflammatory compound belonging to a new class of agents—composite vascular protectants—which also has potential as an anti-diabetic agent.

Mechanism
Succinobucol blocks production of certain inflammatory mediators (e.g., VCAM-1 and MCP-1), which are implicated in atherosclerosis. Succinobucol may reduce or reverse morbidity and mortality of coronary heart disease, as well as the rate of restenosis in stents.
References in periodicals archive ?
AtheroGenics, which has been testing a drug called AGI-1067 against diabetes after it failed for heart disease, said Sept.
Shares in drugs giant AstraZeneca look set for a bumpy ride in the next fortnight, with positive news expected for cholesterol fighter Cres-tor but experimental heart drug AGI-1067 widely tipped to fail in a key study.
The alliance gives AstraZeneca, Europe's third-largest pharmaceutical firm, rights to AGI-1067, a novel pill that is currently undergoing Phase III clinical trials.
on the signing of a significant commercialization agreement for AGI-1067, its novel oral therapy for the treatment of atherosclerosis.
The company currently has 4 vascular protectant programs in development including AGI-1067, an oral agent in Phase II clinical trials for the treatment of retenosis and atherosclerosis.
06, The tiny drug developer is working on a medicine for treating coronary heart disease, and investors are waiting on news about the latest clinical trial of compound AGI-1067.
From the same AGIX report: "The company previously released phase III data on lead compound AGI-1067 that did not meet the primary end point.
6% for the highest (150mg) dose, and continued signs of elevate liver activity give us cause to remain skeptical of the eventual commercial potential of AGI-1067.
The 08 Noteholders believe that the proposal would have permitted AtheroGenics to meet its payment obligations under the 08 Notes and to meet other short- and long-term goals, including completion of the development of AGI-1067 through its second, confirmatory Phase 3 trial, and to avoid defaults of AtheroGenics' other outstanding debt.
CONTENTS: Section 1: Executive Summary Section 2: The Current Market Leaders in T2 Diabetes Section 3: Future Competitive Threats Novel Therapeutics in Late-Stage Development Section 4: Long-Term Potential Competitive Threats Innovative Therapies in Mid-Stage Development Section 5: APPENDIX Products Mentioned: - Alogliptin (SYR-322) - Liraglutide - Saxagliptin - AGI-1067 - Exanatide LAR (exenatide) - Dapagliflozin - Balaglitazone - BI-1356 - rivoglitazone (CS-011) - AVE-0010 - R1583 - AVE-2268 - remogliflozin - PHX1149 - INT131 - albiglutide - Aleglitazar - PF-00734200 - R1579 - TAK-472 (SYR-472) - AMG-222 (ALS 2-0426) - INCB13739 - MB07803 - ISIS 113715 - AZD2207 - DIO-902 - EMD 387008 - indeglitazar - azilsartan - MBX-2044 - CJC-1134-PC - CRx-401 - K-111 - MP-513 - AKP-020 - AVE0847
Nasdaq: AGIX) announced on March 19, 2007 that the ARISE phase III clinical study of AGI-1067 did not show a difference from placebo in its composite primary endpoint of time to first incidence of a composite of major adverse cardiovascular events (MACE).
The leading pipeline candidate is AGI-1067 for atherosclerosis.